{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T18:22:52Z","timestamp":1759602172075},"reference-count":41,"publisher":"Akademiai Kiado Zrt.","issue":"24","license":[{"start":{"date-parts":[[2021,6,13]],"date-time":"2021-06-13T00:00:00Z","timestamp":1623542400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["akjournals.com"],"crossmark-restriction":true},"short-container-title":["OH"],"published-print":{"date-parts":[[2021,6,13]]},"abstract":"<jats:p><jats:bold>\u00d6sszefoglal\u00f3.<\/jats:bold>\n                    <jats:italic>Bevezet\u00e9s:<\/jats:italic> A gliom\u00e1k, ezen bel\u00fcl a glioblastoma kezel\u00e9se\n                    tov\u00e1bbra is megoldatlan onkol\u00f3giai probl\u00e9m\u00e1t jelent. A szekunder szimpt\u00f3m\u00e1s\n                    epilepsziabetegs\u00e9g megjelen\u00e9se pozit\u00edv prognosztikai faktornak tekinthet\u0151 a\n                    korai diagnosztiz\u00e1l\u00e1s \u00e9s az antiepileptikumok potenci\u00e1lis tumorellenes hat\u00e1s\u00e1nak\n                    k\u00f6sz\u00f6nhet\u0151en. A valpro\u00e1t t\u00fal\u00e9l\u00e9st hosszabb\u00edt\u00f3 hat\u00e1sa m\u00e1r t\u00f6bb mint 20 \u00e9ve az\n                    alap- \u00e9s klinikai kutat\u00e1sok t\u00e1rgy\u00e1t k\u00e9pezi. Napjainkban ismert citotoxikus,\n                    proapoptotikus, antiangiogenetikus \u00e9s hiszton-deacetil\u00e1z-g\u00e1tl\u00f3\n                    hat\u00e1smechanizmusa. <jats:italic>C\u00e9lkit\u0171z\u00e9s:<\/jats:italic> Kutat\u00e1sunk c\u00e9lja a valpro\u00e1t\n                    t\u00fal\u00e9l\u00e9st hosszabb\u00edt\u00f3 hat\u00e1s\u00e1nak vizsg\u00e1lata egy hazai gliom\u00e1s betegcsoportban.\n                        <jats:italic>M\u00f3dszer:<\/jats:italic> Egycentrumos, retrospekt\u00edv klinikai vizsg\u00e1latot\n                    v\u00e9gezt\u00fcnk. A vizsg\u00e1latba 122 feln\u0151tt beteget vontunk be, akikn\u00e9l 2000 janu\u00e1rja\n                    \u00e9s 2018 janu\u00e1rja k\u00f6z\u00f6tt supratentorialis glioma miatt m\u0171t\u00e9t t\u00f6rt\u00e9nt, \u00e9s\n                    rohamtev\u00e9kenys\u00e9g miatt antiepileptikumot (valpro\u00e1t, levetiracet\u00e1m, karbamazepin)\n                    szedtek. Egy\u00fattal gy\u00f3gyszert nem szed\u0151 kontrollcsoportot is kialak\u00edtottunk. A\n                    popul\u00e1ci\u00f3t vizsg\u00e1lati \u00e9s kontrollcsoportokra osztottuk 28 : 52 ar\u00e1nyban. Le\u00edr\u00f3\n                    statisztikai, Kaplan\u2013Meier- \u00e9s log-rank anal\u00edzist v\u00e9gezt\u00fcnk.\n                        <jats:italic>Eredm\u00e9nyek:<\/jats:italic> A vizsg\u00e1lt sz\u00f6vettani kateg\u00f3ri\u00e1k t\u00fal\u00e9l\u00e9si\n                    anal\u00edzise az irodalmi adatokkal megegyez\u0151 \u00e9rt\u00e9keket mutatott. A\n                    progresszi\u00f3mentes (PFS: p = 0,031) \u00e9s a teljes (OS: p = 0,027) t\u00fal\u00e9l\u00e9s\n                    tekintet\u00e9ben is szignifik\u00e1ns elt\u00e9r\u00e9s mutatkozott a k\u00fcl\u00f6nb\u00f6z\u0151 antiepileptikumot\n                    szed\u0151 betegcsoportok k\u00f6z\u00f6tt, amely m\u00e9g kifejezettebb\u00e9 v\u00e1lt a valpro\u00e1tot \u00e9s az\n                    egy\u00e9b antiepileptikumot szed\u0151 betegek t\u00fal\u00e9l\u00e9si idej\u00e9nek \u00f6sszehasonl\u00edt\u00e1sa sor\u00e1n\n                    (PFS: p = 0,006; OS: p = 0,015). <jats:italic>K\u00f6vetkeztet\u00e9s:<\/jats:italic> Vizsg\u00e1latunkban\n                    a valpro\u00e1t betegeink PFS- \u00e9s OS-idej\u00e9nek meghosszabbod\u00e1s\u00e1t eredm\u00e9nyezte. Az\n                    irodalmi adatok \u00e9s kutat\u00e1sunk alapj\u00e1n megfontoland\u00f3nak tartjuk a valpro\u00e1t els\u0151\n                    vonalban t\u00f6rt\u00e9n\u0151 alkalmaz\u00e1s\u00e1t onkoter\u00e1pi\u00e1ban r\u00e9szes\u00fcl\u0151, epilepszi\u00e1s, agyi\n                    gliom\u00e1s betegekben. Orv Hetil. 2021; 162(24): 960\u2013967.<\/jats:p>\n                <jats:p><jats:bold>Summary.<\/jats:bold>\n                    <jats:italic>Introduction:<\/jats:italic> Gliomas still prove to be a serious oncological\n                    problem. The presence of epilepsy may present a favorable prognosis due to early\n                    diagnosis and the potential antitumor effects of antiepileptic drugs. The\n                    survival prolongation effect of valproate has been studied for more than 20\n                    years, nowadays its proapoptotic, anti-angiogenetic, cytotoxic and histone\n                    deacetylase inhibitory effects are well known. <jats:italic>Objective:<\/jats:italic> Our\n                    goal was to investigate the survival-enhancing effects of valproate in a\n                    Hungarian patient cohort of primary brain tumors. <jats:italic>Method:<\/jats:italic> A\n                    single-center based retrospective clinical trial was designed. In our study, we\n                    included 122 patients harboring supratentorial glioma who underwent surgery and\n                    experienced seizures between 2000 January and 2018 January. The patients were\n                    grouped by the antiepileptic therapies and survival analysis was performed.\n                        <jats:italic>Results:<\/jats:italic> The Kaplan\u2013Meier curves of the histological\n                    categories showed the survival values consistent with the data of the\n                    literature. The progression-free (PFS: p = 0.031) and the overall (OS: p =\n                    0.027) survival of the antiepileptic drug categories were significantly\n                    different. It was performed by comparing the valproate group and the population\n                    formed by the other groups which also showed a significant increase in the\n                    survival values (PFS: p = 0.006; OS: p = 0.015). <jats:italic>Conclusion:<\/jats:italic>\n                    Our results show that valproate increases the PFS and OS period of glioma\n                    patients in comparison to other antiepileptic drugs. Our data suggest that the\n                    use of valproic acid should be considered as a first-line antiepileptic agent in\n                    certain well-selected epileptic patients with glioma as a supplement to the\n                    oncotherapy. Orv Hetil. 2021; 162(24): 960\u2013967.<\/jats:p>","DOI":"10.1556\/650.2021.32110","type":"journal-article","created":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T10:05:26Z","timestamp":1630404326000},"page":"960-967","update-policy":"http:\/\/dx.doi.org\/10.1556\/policypage.crossmark.crossref.1","source":"Crossref","is-referenced-by-count":2,"title":["A valpro\u00e1tter\u00e1pia t\u00fal\u00e9l\u00e9sre gyakorolt hat\u00e1sa gliom\u00e1s betegekben"],"prefix":"10.1556","volume":"162","author":[{"given":"Tam\u00e1s","family":"Mezei","sequence":"first","affiliation":[{"name":"1 Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Idegseb\u00e9szeti Tansz\u00e9k, Budapest"},{"name":"2 Orsz\u00e1gos Ment\u00e1lis, Ideggy\u00f3gy\u00e1szati \u00e9s Idegseb\u00e9szeti Int\u00e9zet, Budapest, Amerikai \u00fat 57., 1145"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D\u00e1vid","family":"M\u00e9sz\u00e1ros","sequence":"additional","affiliation":[{"name":"1 Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Idegseb\u00e9szeti Tansz\u00e9k, Budapest"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P\u00e9ter","family":"Pollner","sequence":"additional","affiliation":[{"name":"3 MTA\u2013ELTE Statisztikus \u00e9s Biol\u00f3giai Fizika Kutat\u00f3csoport, Budapest"},{"name":"4 Semmelweis Egyetem, Eg\u00e9szs\u00e9g\u00fcgyi Menedzserk\u00e9pz\u0151 K\u00f6zpont, Budapest"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Attila","family":"Bag\u00f3","sequence":"additional","affiliation":[{"name":"2 Orsz\u00e1gos Ment\u00e1lis, Ideggy\u00f3gy\u00e1szati \u00e9s Idegseb\u00e9szeti Int\u00e9zet, Budapest, Amerikai \u00fat 57., 1145"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Imre","family":"Fedorcs\u00e1k","sequence":"additional","affiliation":[{"name":"2 Orsz\u00e1gos Ment\u00e1lis, Ideggy\u00f3gy\u00e1szati \u00e9s Idegseb\u00e9szeti Int\u00e9zet, Budapest, Amerikai \u00fat 57., 1145"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P\u00e9ter","family":"Banczerowski","sequence":"additional","affiliation":[{"name":"1 Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Idegseb\u00e9szeti Tansz\u00e9k, Budapest"},{"name":"2 Orsz\u00e1gos Ment\u00e1lis, Ideggy\u00f3gy\u00e1szati \u00e9s Idegseb\u00e9szeti Int\u00e9zet, Budapest, Amerikai \u00fat 57., 1145"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L\u00e1szl\u00f3","family":"Sipos","sequence":"additional","affiliation":[{"name":"1 Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Idegseb\u00e9szeti Tansz\u00e9k, Budapest"},{"name":"2 Orsz\u00e1gos Ment\u00e1lis, Ideggy\u00f3gy\u00e1szati \u00e9s Idegseb\u00e9szeti Int\u00e9zet, Budapest, Amerikai \u00fat 57., 1145"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"425","reference":[{"key":"ref0","unstructured":"1 Lukas RV, Wainwright DA, Ladomersky E, et al. Newly diagnosed glioblastoma: a review on clinical management. Oncology (Williston Park, United States) 2019; 33: 91-100."},{"key":"ref1","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1001\/jama.2013.280319","article-title":"Glioblastoma and other malignant gliomas: a clinical review","volume":"310","author":"Omuro A","year":"2013","unstructured":"2 Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review. JAMA 2013; 310: 1842-1850.","journal-title":"JAMA"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"3 Stupp","year":"2005","unstructured":"3 Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352: 987-996.","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","article-title":"Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial","volume":"10","author":"4 Stupp","year":"2009","unstructured":"4 Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009; 10: 459-466.","journal-title":"Lancet Oncol"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"5 Czigl\u00e9czki G, Sink\u00f3 D, Benk\u0151 Zs, et al. The effect of bevacizumab monotherapy on progression-free survival in recurrent glioblastoma. [A bevacizumab-monoter\u00e1pia hat\u00e1sa a progresszi\u00f3mentes t\u00fal\u00e9l\u00e9sre rekurrens glioblastom\u00e1ban szenved\u0151 betegek eset\u00e9ben.] Ideggy\u00f3gy Szle. 2019; 72: 153-158. [Hungarian]","DOI":"10.18071\/isz.72.0153"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/B978-0-12-802997-8.00016-5","article-title":"Epilepsy and brain tumors","volume":"134","author":"6 Englot","year":"2016","unstructured":"6 Englot DJ, Chang EF, Vecht CJ. Epilepsy and brain tumors. Handb Clin Neurol. 2016; 134: 267-285.","journal-title":"Handb Clin Neurol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.jocn.2003.09.018","article-title":"Significance of chronic epilepsy in glial tumors and correlation with surgical strategies","volume":"11","author":"7 Kim","year":"2004","unstructured":"7 Kim OJ, Yong Ahn J, Chung YS, et al. Significance of chronic epilepsy in glial tumors and correlation with surgical strategies. J Clin Neurosci. 2004; 11: 702-705.","journal-title":"J Clin Neurosci"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"8 Lee JW, Wen PY, Hurwitz S, et al. Morphological characteristics of brain tumors causing seizures. Arch Neurol. 2010; 67: 336-342.","DOI":"10.1001\/archneurol.2010.2"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s00401-004-0833-3","article-title":"An isomorphic subtype of long-term epilepsy-associated astrocytomas associated with benign prognosis","volume":"107","author":"9 Bl\u00fcmcke","year":"2004","unstructured":"9 Bl\u00fcmcke I, Luyken C, Urbach H, et al. An isomorphic subtype of long-term epilepsy-associated astrocytomas associated with benign prognosis. Acta Neuropathol. 2004; 107: 381-388.","journal-title":"Acta Neuropathol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/S0959-8049(97)00374-2","article-title":"Prevalence and prognostic significance of epilepsy in patients with gliomas","volume":"34","author":"10 Lote","year":"1998","unstructured":"10 Lote K, Stenwig AE, Skullerud K, et al. Prevalence and prognostic significance of epilepsy in patients with gliomas. Eur J Cancer 1998; 34: 98-102.","journal-title":"Eur J Cancer"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"11 Stupp R, Janzer RC, Hegi ME, et al. Prognostic factors for low-grade gliomas. Semin Oncol. 2003; 30(6 Suppl 19): 23-28.","DOI":"10.1053\/j.seminoncol.2003.11.029"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s11060-018-2862-0","article-title":"Tumor-related epilepsy: epidemiology, pathogenesis and management","volume":"139","author":"12 Chen","year":"2018","unstructured":"12 Chen DY, Chen CC, Crawford JR, et al. Tumor-related epilepsy: epidemiology, pathogenesis and management. J Neurooncol. 2018; 139: 13-21.","journal-title":"J Neurooncol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"6969","DOI":"10.1093\/emboj\/20.24.6969","article-title":"Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells","volume":"20","author":"13 G\u00f6ttlicher","year":"2001","unstructured":"13 G\u00f6ttlicher M, Minucci S, Zhu P, et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J. 2001; 20: 6969-6978.","journal-title":"EMBO J"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"361","DOI":"10.2174\/138945010790711923","article-title":"Valproic acid in the complex therapy of malignant tumors","volume":"11","author":"14 Hrebackova","year":"2010","unstructured":"14 Hrebackova J, Hrabeta J, Eckschlager T. Valproic acid in the complex therapy of malignant tumors. Curr Drug Targets 2010; 11: 361-379.","journal-title":"Curr Drug Targets"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s11060-014-1713-x","article-title":"The effect of valproic acid in combination with irradiation and temozolomide on primary human glioblastoma cells","volume":"122","author":"15 Hosein","year":"2015","unstructured":"15 Hosein AN, Lim YC, Day B, et al. The effect of valproic acid in combination with irradiation and temozolomide on primary human glioblastoma cells. J Neurooncol. 2015; 122: 263-271.","journal-title":"J Neurooncol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1667\/RR1245.1","article-title":"Histone deacetylase inhibitors protect against and mitigate the lethality of total-body irradiation in mice","volume":"169","author":"16 Brown","year":"2008","unstructured":"16 Brown SL, Kolozsvary A, Liu J, et al. Histone deacetylase inhibitors protect against and mitigate the lethality of total-body irradiation in mice. Radiat Res. 2008; 169: 474-478.","journal-title":"Radiat Res"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1093\/neuonc\/nou087","article-title":"The epidemiology of glioma in adults: a \"state of the science review\"","volume":"16","author":"17 Ostrom","year":"2014","unstructured":"17 Ostrom QT, Bauchet L, Davis FG, et al. The epidemiology of glioma in adults: a \"state of the science review\". Neurooncol. 2014; 16: 896-913.","journal-title":"Neurooncol"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"18 Nayak L, Reardon DA. High-grade gliomas. Continuum lifelong learning. Neurooncology 2017; 23: 1548-1563.","DOI":"10.1212\/CON.0000000000000554"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"19 Schiff D. Low-grade gliomas. Continuum lifelong learning. Neurooncology 2017; 23: 1564-1579.","DOI":"10.1212\/CON.0000000000000537"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"4926","DOI":"10.1038\/s41598-020-61701-z","article-title":"Optimal timing of radiotherapy following gross total or subtotal resection of glioblastoma: a real-world assessment using the National Cancer Database","volume":"10","author":"20 Buszek","year":"2020","unstructured":"20 Buszek SM, Al Feghali KA, Elhalawani H, et al. Optimal timing of radiotherapy following gross total or subtotal resection of glioblastoma: a real-world assessment using the National Cancer Database. Sci Rep. 2020; 10: 4926.","journal-title":"Sci Rep"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.jocn.2019.05.013","article-title":"The impact of timing of adjuvant therapy on survival for patients with glioblastoma: an analysis of the National Cancer Database","volume":"66","author":"21 Amsbaugh","year":"2019","unstructured":"21 Amsbaugh MJ, Yusuf M, Gaskins J, et al. The impact of timing of adjuvant therapy on survival for patients with glioblastoma: an analysis of the National Cancer Database. J Clin Neurosci. 2019; 66: 92-99.","journal-title":"J Clin Neurosci"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1194\/jlr.R046797","article-title":"The ketogenic diet for the treatment of malignant glioma","volume":"56","author":"Woolf EC","year":"2015","unstructured":"22 Woolf EC, Scheck AC. The ketogenic diet for the treatment of malignant glioma. J Lipid Res. 2015; 56: 5-10.","journal-title":"J Lipid Res"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s42003-019-0455-x","article-title":"Therapeutic benefit of combining calorie-restricted ketogenic diet and glutamine targeting in late-stage experimental glioblastoma","volume":"2","author":"23 Mukherjee","year":"2019","unstructured":"23 Mukherjee P, Augur ZM, Li M, et al. Therapeutic benefit of combining calorie-restricted ketogenic diet and glutamine targeting in late-stage experimental glioblastoma. Commun Biol. 2019; 2: 200.","journal-title":"Commun Biol"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"24 van der Louw EJ, Olieman JF, Catsman-Berrevoets CE, et al. Ketogenic diet treatment as adjuvant to standard treatment of glioblastoma multiforme: a feasibility and safety study. Ther Adv Med Oncol. 2019; 11: 1758835919853958. Doi: 10.1177\/1758835919853958.","DOI":"10.1177\/1758835919853958"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"25 van der Louw EJ, Reddingius RE, Olieman JF, et al. Ketogenic diet treatment in recurrent diffuse intrinsic pontine glioma in children: a safety and feasibility study. Pediatr Blood Cancer 2019; 66: e27561.","DOI":"10.1002\/pbc.27561"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s11060-016-2056-6","article-title":"The effects of antiepileptic drugs on the growth of glioblastoma cell lines","volume":"127","author":"26 Lee","year":"2016","unstructured":"26 Lee CY, Lai HY, Chiu A, et al. The effects of antiepileptic drugs on the growth of glioblastoma cell lines. J Neurooncol. 2016; 127: 445-453.","journal-title":"J Neurooncol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/j.ijrobp.2015.04.038","article-title":"A phase 2 study of concurrent radiation therapy, temozolomide, and the histone deacetylase inhibitor valproic acid for patients with glioblastoma","volume":"92","author":"27 Krauze","year":"2015","unstructured":"27 Krauze AV, Myrehaug SD, Chang MG, et al. A phase 2 study of concurrent radiation therapy, temozolomide, and the histone deacetylase inhibitor valproic acid for patients with glioblastoma. Int J Radiat Oncol Biol Phys. 2015; 92: 986-992.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s00228-016-2167-1","article-title":"Valproic acid reduces hair loss and improves survival in patients receiving temozolomide-based radiation therapy for high-grade glioma","volume":"73","author":"28 Watanabe","year":"2017","unstructured":"28 Watanabe S, Kuwabara Y, Suehiro S, et al. Valproic acid reduces hair loss and improves survival in patients receiving temozolomide-based radiation therapy for high-grade glioma. Eur J Clin Pharmacol. 2017; 73: 357-363.","journal-title":"Eur J Clin Pharmacol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1200\/JCO.2015.63.6563","article-title":"Does valproic acid or levetiracetam improve survival in glioblastoma? A pooled analysis of prospective clinical trials in newly diagnosed glioblastoma","volume":"34","author":"29 Happold","year":"2016","unstructured":"29 Happold C, Gorlia T, Chinot O, et al. Does valproic acid or levetiracetam improve survival in glioblastoma? A pooled analysis of prospective clinical trials in newly diagnosed glioblastoma. J Clin Oncol. 2016; 34: 731-739.","journal-title":"J Clin Oncol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"347","DOI":"10.3109\/02688697.2011.638996","article-title":"Effect of valproic acid on the outcome of glioblastoma multiforme","volume":"26","author":"30 Tsai","year":"2012","unstructured":"30 Tsai HC, Wei KC, Tsai CN, et al. Effect of valproic acid on the outcome of glioblastoma multiforme. Br J Neurosurg. 2012; 26: 347-354.","journal-title":"Br J Neurosurg"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s11060-016-2054-8","article-title":"Valproic acid, compared to other antiepileptic drugs, is associated with improved overall and progression-free survival in glioblastoma but worse outcome in grade II\/III gliomas treated with temozolomide","volume":"127","author":"31 Redjal","year":"2016","unstructured":"31 Redjal N, Reinshagen C, Le A, et al. Valproic acid, compared to other antiepileptic drugs, is associated with improved overall and progression-free survival in glioblastoma but worse outcome in grade II\/III gliomas treated with temozolomide. J Neurooncol. 2016; 127: 505-514.","journal-title":"J Neurooncol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"556","DOI":"10.3109\/08880018.2011.563774","article-title":"Potential role for valproate in the treatment of high-risk brain tumors of childhood-results from a retrospective observational cohort study","volume":"28","author":"32 Felix","year":"2011","unstructured":"32 Felix FH, Trompieri NM, de Araujo OL, et al. Potential role for valproate in the treatment of high-risk brain tumors of childhood-results from a retrospective observational cohort study. Pediatr Hematol Oncol. 2011; 28: 556-570.","journal-title":"Pediatr Hematol Oncol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s00381-012-1997-0","article-title":"Survival of children with malignant brain tumors receiving valproate: a retrospective study","volume":"29","author":"33 Felix","year":"2013","unstructured":"33 Felix FH, de Araujo OL, Da Trindade KM, et al. Survival of children with malignant brain tumors receiving valproate: a retrospective study. Child's Nerv Syst. 2013; 29: 195-197.","journal-title":"Child s Nerv Syst"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1002\/cncr.24730","article-title":"Intensive chemotherapy improves survival in pediatric high-grade glioma after gross total resection: results of the HIT-GBM-C protocol","volume":"116","author":"34 Wolff","year":"2010","unstructured":"34 Wolff JE, Driever PH, Erdlenbruch B, et al. Intensive chemotherapy improves survival in pediatric high-grade glioma after gross total resection: results of the HIT-GBM-C protocol. Cancer 2010; 116: 705-712.","journal-title":"Cancer"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s11060-008-9662-x","article-title":"Valproic acid was well tolerated in heavily pretreated pediatric patients with high-grade glioma","volume":"90","author":"35 Wolff","year":"2008","unstructured":"35 Wolff JE, Kramm C, Kortmann RD, et al. Valproic acid was well tolerated in heavily pretreated pediatric patients with high-grade glioma. J Neurooncol. 2008; 90: 309-314.","journal-title":"J Neurooncol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.eplepsyres.2003.11.001","article-title":"Effect of valproate on hemostatic function in patients with traumatic brain injury","volume":"57","author":"36 Anderson","year":"2003","unstructured":"36 Anderson GD, Temkin NR, Chandler WL, et al. Effect of valproate on hemostatic function in patients with traumatic brain injury. Epilepsy Res. 2003; 57: 111-119.","journal-title":"Epilepsy Res"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1097\/MBC.0b013e3282f3f9ec","article-title":"High incidence of vaproate-induced coagulation disorders in children receiving valproic acid: a prospective study","volume":"19","author":"37 Koenig","year":"2008","unstructured":"37 Koenig S, Gerstner T, Keller A, et al. High incidence of vaproate-induced coagulation disorders in children receiving valproic acid: a prospective study. Blood Coagul Fibrinolysis 2008; 19: 375-382.","journal-title":"Blood Coagul Fibrinolysis"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/0387-7604(95)00139-5","article-title":"Hematologic manifestations and impaired liver synthetic function during valproate monotherapy","volume":"18","author":"38 Hauser","year":"1996","unstructured":"38 Hauser E, Seidl R, Freilinger M, et al. Hematologic manifestations and impaired liver synthetic function during valproate monotherapy. Brain Dev. 1996; 18: 105-109.","journal-title":"Brain Dev"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/S0887-8994(99)00060-0","article-title":"Platelet count and function in children receiving sodium valproate","volume":"21","author":"39 Verrotti","year":"1999","unstructured":"39 Verrotti A, Greco R, Matera V, et al. Platelet count and function in children receiving sodium valproate. Pediatr Neurol. 1999; 21: 611-614.","journal-title":"Pediatr Neurol"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1111\/j.1528-1167.2007.01429.x","article-title":"Valproate-induced thrombocytopenia: a prospective monotherapy study","volume":"49","author":"Nasreddine W","year":"2008","unstructured":"40 Nasreddine W, Beydoun A. Valproate-induced thrombocytopenia: a prospective monotherapy study. Epilepsia 2008; 49: 438-445.","journal-title":"Epilepsia"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.jpsychires.2004.10.007","article-title":"Lithium and valproic acid treatments reduce PKC activation and receptor-G protein coupling in platelets of bipolar manic patients","volume":"39","author":"41 Hahn","year":"2005","unstructured":"41 Hahn CG, Umapathy, Wang HY, et al. Lithium and valproic acid treatments reduce PKC activation and receptor-G protein coupling in platelets of bipolar manic patients. J Psychiatr Res. 2005; 39: 355-363.","journal-title":"J Psychiatr Res"}],"container-title":["Orvosi Hetilap"],"original-title":[],"link":[{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/162\/24\/article-p960.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/akjournals.com\/downloadpdf\/journals\/650\/162\/24\/article-p960.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T08:57:44Z","timestamp":1698742664000},"score":1,"resource":{"primary":{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/162\/24\/article-p960.xml"}},"subtitle":["Alternat\u00edv ter\u00e1pi\u00e1s lehet\u0151s\u00e9g a radiokemoter\u00e1pia eredm\u00e9nyess\u00e9g\u00e9nek\n                        jav\u00edt\u00e1s\u00e1ra"],"short-title":[],"issued":{"date-parts":[[2021,6,13]]},"references-count":41,"journal-issue":{"issue":"24"},"URL":"https:\/\/doi.org\/10.1556\/650.2021.32110","relation":{},"ISSN":["0030-6002","1788-6120"],"issn-type":[{"value":"0030-6002","type":"print"},{"value":"1788-6120","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,13]]}}}